Category: Cancer

Dr. Mikhail Blagosklonny and His Vigilant Fight Against Ageing

Dr. Blagosklonny has been interested in the world of medicine from a very young age, explaining why he acquired both his M.D. in Internal Medicine and Ph.D. in experimental medicine and cardiology from the First Pavlov State Medical University Of St. Petersburg. His performance was so exemplary to the point that he qualified for a job at New York Medical College in Valhalla as an associate professor in 2002.Once he was done with that, Dr. Blagosklonny went on to challenge himself with a position in Ordway Research Institute as a Senior Scientist right before ending up at Roswell Park Cancer Institute as an Oncology Professor in 2009. That was when his research in rapamycin intensified and made enormous progress.Dr. Blagosklonny has been in the business of making sure that he finds much better and less invasive ways of treating cancer. He ensured that he was always in a position to get work done by developing an anti aging drug called rapamycin, one that he later wrote a paper on about how it can be utilized properly.

Dr. Blagosklonny wrote that the use of rapamycin would go a long way in slowing the aging rate as it targets particular cells that trigger the latter hence making the entire process slower. In layman terms, the medication has some rather straightforward modus operandi which acts on the principle of protecting healthy cells from damage as the cancer cells are attacked.The use of rapamycin, Dr. Blagosklonny stated, will most likely affect the TOR signaling in aging and cancer, which can without a doubt boost the lifespan of the consumer. He attributed old age to cells being damaged, and since our bodies to rejuvenate them as fast as possible, they die off at a much faster rate than normal which is the cause of aging.When healthy cells are protected, then the body functions will always work which will result in a boost in the immune system. And since he had spent a couple of years studying bio gerontology (which is the science of studying the underlying body mechanisms that result to aging).

Dr. Blagosklonny has been able to consider the kind of effects that patients who consume rapamycin are having, both in the short and long term.Apart from being an adroit researcher and scientist, Dr. Blagosklonny is also known for his impressive writing as reflected in quite some publications that sparked a worldwide interest once published. Some of his publications include Cancer Biology & Therapy where he was both a contributor and editor.In total, the brilliant oncology specialist has written close to 270 pages in total, making sure that he shares his knowledge with millions of people around the globe. The latter has resulted to his effective outsourcing over 25,000 citations over the years.Others include Aging, where he was the editor in chief as well as Oncotarget. He also was the editor in chief in Cell Cycle after he carried out an in-depth research on the subject matter. In all the above publications, all of which Dr. Blagosklonny (@Mikhail Blagosklonny) is responsible for making happen, he always made sure that he recommends the use of rapamycin.

How Eric Lefkofsky’s Company is Changing the War on Cancer

Four in 10 Americans are expected to develop cancer at some point in their lives. Fortunately, much progress has been made in the diagnosis and treatment of this dreaded disease, and many of the advances in this area are attributable to the work done by such companies as Tempus. This Chicago-based firm has developed a method that can improve cancer treatment through the principle of human genome sequencing.

Although many types of cancer treatment are available today, the effectiveness of any one method often comes down to understanding the specific needs of the person receiving treatment. Tempus has satisfied these needs by developing a platform that can analyze the clinical and molecular composition of individual patients. The result is a major transformation in the way medical health care delivered.

Eric Lefkofsky, who helped establish Tempus, faced a personal crisis when his wife Liz was diagnosed with breast cancer. It was then that he also learned of the inadequacies in the manner that cancer data was being collected and stored. This problem was overcome by the software that would be developed by his company. Possessing language and character recognition capabilities, this software enabled the faster processing of patient information that is often recorded by hand. Notes could thus be transformed into structured data that could be used in the treatment process.

The work by Tempus will help shift treatment strategies to techniques targeting molecules and cells. The end result will be the development of specific treatments that can be more effective and less costly. Such personalized methods may eventually extend from cancer to the treatment of other diseases.

Although he has been long associated with Chicago, Eric Lefkofsky was born in Detroit. A graduate of the University of Michigan Law School, he would later teach at Kellstadt Graduate School of Business, a division of DePaul University, and at the Kellogg School of Business, which is part of Northwestern University. He is currently adjunct professor at the Booth School of Business division of the University of Chicago.

In addition to his academic service, the 47-year-old entrepreneur serves on the boards of some notable organizations, including the Ann and Robert H. Lurie Children’s Memorial Hospital and the Art Institute of Chicago.

About Eric Lefkofsky: lefkofskyfoundation.com/about-eric-lefkofsky/